| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Human Endogenous Metabolite
H-D-His-OH is classified as a D-α-amino acid belonging to the histidine family. It does not have a specific biological receptor target. Its primary application is as a specialized chiral building block in peptide synthesis for introducing D-histidine residues. Unlike its naturally abundant L-counterpart, D-histidine is a non-proteinogenic amino acid that occurs in specific microbial peptides. |
|---|---|
| ln Vitro |
In vitro activity for H-D-His-OH is primarily as a peptide synthesis reagent. Amino acids and amino acid derivatives have been commercially used as ergogenic supplements. They influence the secretion of anabolic hormones, supply of fuel during exercise, mental performance during stress-related tasks and prevent exercise-induced muscle damage. H-D-His-OH itself is not directly biologically active; its utility is in preparing D-histidine-containing peptides for subsequent biological evaluation.
|
| ln Vivo |
In vivo activity data for H-D-His-OH as a standalone compound is not applicable. It is a non-proteinogenic D-amino acid used exclusively as a research building block and is not intended for direct in vivo administration. Peptides synthesized using this building block may be evaluated in animal models for various biological activities. The D-configuration can confer proteolytic stability to peptides.
|
| Enzyme Assay |
In vitro enzyme/receptor binding protocols for H-D-His-OH involve studying its interactions with enzymes involved in amino acid metabolism. The compound can be used in receptor binding studies to investigate the effects of D-configuration on ligand-receptor interactions. For enzyme activity studies, H-D-His-OH can be used as a substrate or inhibitor to probe enzyme specificity.
|
| Cell Assay |
Cell culture protocols for H-D-His-OH involve dissolving the compound in sterile water or cell culture medium. Cells are treated with concentrations ranging from 0.1-100 µM for 24-72 hours. Effects on cell viability, proliferation, and signaling pathways are assessed. The compound can be used to study amino acid transport and metabolism in cell models.
|
| Animal Protocol |
In vivo animal study protocols for H-D-His-OH involve administration via oral gavage or injection in saline. Dosing typically ranges from 10-100 mg/kg depending on the study. Studies may assess effects on protein metabolism and amino acid homeostasis. Blood and tissue samples are collected for analysis of compound distribution and metabolite levels.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of H-D-His-OH are characteristic of small amino acids. The compound has a molecular weight of 155.16 g/mol, formula C6H9N3O2, and CAS number 351-50-8. Melting point is 287°C. Density is 1.423 g/cm3. Storage is recommended at room temperature in a cool, dark place below 15°C.
|
| Toxicity/Toxicokinetics |
Limited toxicological data is available for H-D-His-OH. The compound is for research use only and is not intended for human therapeutic use. Standard safety precautions for handling amino acids should be observed. No specific toxicity studies have been reported.
|
| References | |
| Additional Infomation |
D-histidine is an optically active histidine with a D configuration. It is a metabolite of Saccharomyces cerevisiae. It is a D-α-amino acid belonging to the histidine family. It is the conjugate base of D-histidine ononium (1+). It is the conjugate acid of D-histidine anion (1-). It is an enantiomer of L-histidine. It is a tautomer of the D-histidine zwitterion. The presence of D-histidine in Saccharomyces cerevisiae has been reported, and relevant data are available for reference.
H-D-His-OH (CAS#: 351-50-8) is also known as D-Histidine, (R)-2-Amino-3-(4-imidazolyl)propionic acid, and D-2-Amino-3-(4-imidazolyl)propionic acid. Its molecular formula is C6H9N3O2. It is a non-proteinogenic D-amino acid used as a chiral building block in peptide synthesis. It has no approved therapeutic indications. |
| Molecular Formula |
C6H9N3O2
|
|---|---|
| Molecular Weight |
155.1546
|
| Exact Mass |
155.069
|
| CAS # |
351-50-8
|
| PubChem CID |
71083
|
| Appearance |
White to light yellow powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
458.9±35.0 °C at 760 mmHg
|
| Melting Point |
287ºC
|
| Flash Point |
231.3±25.9 °C
|
| Vapour Pressure |
0.0±1.2 mmHg at 25°C
|
| Index of Refraction |
1.615
|
| LogP |
-1.26
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
11
|
| Complexity |
151
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O([H])C([C@@]([H])(C([H])([H])C1=C([H])N=C([H])N1[H])N([H])[H])=O
|
| InChi Key |
HNDVDQJCIGZPNO-RXMQYKEDSA-N
|
| InChi Code |
InChI=1S/C6H9N3O2/c7-5(6(10)11)1-4-2-8-3-9-4/h2-3,5H,1,7H2,(H,8,9)(H,10,11)/t5-/m1/s1
|
| Chemical Name |
(2R)-2-amino-3-(1H-imidazol-5-yl)propanoic acid
|
| Synonyms |
D-Histidine; H-D-His-OH
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~50 mg/mL (~322.27 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.4454 mL | 32.2269 mL | 64.4538 mL | |
| 5 mM | 1.2891 mL | 6.4454 mL | 12.8908 mL | |
| 10 mM | 0.6445 mL | 3.2227 mL | 6.4454 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
